[Effect of aluminium-hydroxide-containing antacids on the intestinal absorption of iron in patients on long-term dialysis].
In 6 patients on maintenance hemodialysis the influence of an aluminium hydroxyde containing antacid (administered to prevent hyperphosphatemia) on the intestinal absorption of iron was measured with 59Fe and with a whole body counter. Iron absorption was 3.4% of the dose administered (geometric mean) while the patients were on antacids. After omission of the medication it rose slightly on 4.1%, the difference being not statistically significant (p greater than 0.5). It is concluded that aluminium hydroxyde containing antacids do not impair intestinal iron absorption in patients on maintenance hemodialysis.
D000328:Adult; D000536:Aluminum Hydroxide / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D005260:Female; D006400:Hematocrit; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007501:Iron / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors
D000536:Aluminum Hydroxide; D007501:Iron
Der Einfluss aluminiumhydroxyd-haltiger Antazida auf die enterale Eisenresorption von Langzeitdialysepatienten.